Mariano R Gabri

Summary

Affiliation: Universidad Nacional de Quilmes
Country: Argentina

Publications

  1. ncbi request reprint Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model
    Mariano R Gabri
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Bernal B1876BXD, Buenos Aires, Argentina
    J Cancer Res Clin Oncol 128:669-77. 2002
  2. ncbi request reprint Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity
    Marcelo D Guthmann
    Immunogenetics Division, Hospital de Clinicas, University of Buenos Aires, Buenos Aires, Argentina
    J Immunother 27:442-51. 2004
  3. ncbi request reprint Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model
    Mariano R Gabri
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Argentina
    Clin Cancer Res 12:7092-8. 2006
  4. pmc Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines
    Mariano R Gabri
    Laboratory of Molecular Oncology, Quilmes National University, Roque Saenz Pena 352, Bernal, B1876BXD, Argentina
    J Exp Clin Cancer Res 28:146. 2009
  5. ncbi request reprint Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides
    Valeria I Segatori
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, R Sáenz Peña 352, Bernal B1876BXD Buenos Aires, Argentina
    In Vivo 26:609-17. 2012
  6. ncbi request reprint Molecular detection of circulating tyrosinase mRNA: optimization in a preclinical xenograft mouse melanoma model and further evaluation in samples from advanced melanoma patients
    Mariano R Gabri
    Laboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina
    Int J Mol Med 21:555-9. 2008
  7. pmc Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer
    Alejandra M Scursoni
    Departament of Pathology, Pediatric Hospital Prof Dr Juan P Garrahan, and Laboratory of Molecular Oncology, Quilmes National University, C1245AAM Buenos Aires, Argentina
    Clin Dev Immunol 2011:245181. 2011
  8. doi request reprint Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma
    Viviana E Laurent
    Laboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina
    Mol Med Report 3:253-9. 2010
  9. pmc Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer
    Valeria I Segatori
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University Buenos Aires, Argentina
    Front Oncol 2:160. 2012
  10. doi request reprint Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry
    Alejandra M Scursoni
    Pathology Department, Pediatric Hospital, Prof Dr Juan P Garrahan, Buenos Aires, Argentina
    Pediatr Dev Pathol 13:18-23. 2010

Collaborators

  • Circe Mesa
  • D F Alonso
  • Roberto J Bitton
  • Guillermo Chantada
  • Zaima Mazorra Herrera
  • Valeria I Segatori
  • Alejandra M Scursoni
  • Sandra Camarero
  • Daniel E Gomez
  • Ana M Vazquez
  • Laura L Otero
  • Laura Galluzzo
  • María Teresa G de Dávila
  • Viviana E Laurent
  • Luis Enrique Fernandez
  • Saily Alfonso
  • Ana de la Torre
  • Rosa M Diaz
  • Elia Neninger
  • Rolando Perez
  • Marcelo D Guthmann
  • Fabiana Lubieniecki
  • Jessica Lopez
  • Claudia Sampor
  • Ana Maria Vazquez
  • Norma Pozzo
  • María Labraga
  • Valeria Vazquez
  • Cristina Mateo De Acosta
  • Maria T G de Davila
  • Giselle Saurez
  • Alain Diaz
  • Darien Toledo
  • Eduardo Santiesteban
  • Angel M Alfonso
  • Jose L Rodriguez
  • Roberto E Gomez
  • María del Carmen Barroso
  • Tania Combet
  • Amparo E Macias
  • Ana M Hernández
  • Frank Aguirre
  • Eduardo Suarez
  • Rolando Rives
  • Carmen Viada
  • Kirenia Pérez
  • Barbara Wilkinson
  • Gabriela Cinat
  • Leonardo Koliren
  • Ariel J L Carnero
  • Leonardo Fainboim
  • Daniel Lewi

Detail Information

Publications13

  1. ncbi request reprint Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model
    Mariano R Gabri
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Bernal B1876BXD, Buenos Aires, Argentina
    J Cancer Res Clin Oncol 128:669-77. 2002
    ..To examine the role of GM3 monosialoganglioside and sialic acid in the antitumor activity of a vaccine based on GM3, hydrophobically conjugated with the outer-membrane-protein complex from Neisseria meningitidis (GM3/VSSP)...
  2. ncbi request reprint Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity
    Marcelo D Guthmann
    Immunogenetics Division, Hospital de Clinicas, University of Buenos Aires, Buenos Aires, Argentina
    J Immunother 27:442-51. 2004
    ....
  3. ncbi request reprint Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model
    Mariano R Gabri
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Argentina
    Clin Cancer Res 12:7092-8. 2006
    ..Our aim was to explore the antitumor properties of perioperative GM3/VSSP vaccination in a preclinical mouse model...
  4. pmc Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines
    Mariano R Gabri
    Laboratory of Molecular Oncology, Quilmes National University, Roque Saenz Pena 352, Bernal, B1876BXD, Argentina
    J Exp Clin Cancer Res 28:146. 2009
    ..N-glycolylneuraminic acid (NeuGc) is synthesized by the cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH), an enzyme expressed in all mammals except humans. In mice, this sugar is synthesized in several somatic tissues...
  5. ncbi request reprint Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides
    Valeria I Segatori
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, R Sáenz Peña 352, Bernal B1876BXD Buenos Aires, Argentina
    In Vivo 26:609-17. 2012
    ..Cancer vaccines are designed to modulate immunological responses against tumor cells through the presentation of tumor antigens...
  6. ncbi request reprint Molecular detection of circulating tyrosinase mRNA: optimization in a preclinical xenograft mouse melanoma model and further evaluation in samples from advanced melanoma patients
    Mariano R Gabri
    Laboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina
    Int J Mol Med 21:555-9. 2008
    ..Baseline tyrosinase expression was significantly associated with disease progression after 12 months, and sequential determination during follow-up of the remaining disease-free patients showed a progressive increase of negative results...
  7. pmc Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer
    Alejandra M Scursoni
    Departament of Pathology, Pediatric Hospital Prof Dr Juan P Garrahan, and Laboratory of Molecular Oncology, Quilmes National University, C1245AAM Buenos Aires, Argentina
    Clin Dev Immunol 2011:245181. 2011
    ..The present study evidenced the expression of NeuGc-GM3 in a high proportion of neuroectodermal tumors, suggesting its potential utility as a specific target of immunotherapy...
  8. doi request reprint Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma
    Viviana E Laurent
    Laboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina
    Mol Med Report 3:253-9. 2010
    ..Hence, GD2 synthase mRNA detection through an optimized nested RT-PCR assay is a promising tool for the assessment of minimal disseminated disease in enucleated patients...
  9. pmc Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer
    Valeria I Segatori
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University Buenos Aires, Argentina
    Front Oncol 2:160. 2012
    ..Our preclinical data provide support for the combination of chemotherapy with the anti-idiotype mAb racotumomab, and also reinforce the biological significance of NeuGc in lung cancer...
  10. doi request reprint Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry
    Alejandra M Scursoni
    Pathology Department, Pediatric Hospital, Prof Dr Juan P Garrahan, Buenos Aires, Argentina
    Pediatr Dev Pathol 13:18-23. 2010
    ..The present study evidenced the expression of NeuGc-GM3 in a high proportion of Wilms tumors, suggesting its potential utility as a specific target of immunotherapy...
  11. ncbi request reprint Cancer vaccines: an update with special focus on ganglioside antigens
    Roberto J Bitton
    M D Unidad de Inmunoterapia, Departamento de Inmunogenetica, Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
    Oncol Rep 9:267-76. 2002
    ..We have already begun a phase II program in several neoplastic diseases, with all three vaccines...
  12. ncbi request reprint 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients
    Saily Alfonso
    Celestino Hernández Robau Hospital, Villa Clara, Cuba
    Cancer Biol Ther 6:1847-52. 2007
    ..50 months from starting vaccination. In contrast, the median survival time calculated for patients who started vaccination with progressive disease and/or a PS2 was 6.50 months...
  13. ncbi request reprint Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial
    Elia Neninger
    Hermanos Amejeiras Hospital, Havana City, Cuba 10300
    Cancer Biol Ther 6:145-50. 2007
    ..A prolonged survival was observed in several patients treated with the anti-idiotype vaccine. No evidence of serious adverse effects was found...